Literature DB >> 26632165

Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction.

Takuya Shimizu1, Manabu Uematsu, Toru Yoshizaki, Jun-Ei Obata, Takamitsu Nakamura, Daisuke Fujioka, Kazuhiro Watanabe, Yosuke Watanabe, Kiyotaka Kugiyama.   

Abstract

AIM: Although plasminogen activator inhibitor-1 (PAI-1) is abundantly expressed in infarcted myocardium, the pathogenic role of myocardial PAI-1 remains unknown. This study examined whether PAI-1 in the infarcted lesion contributes to coronary endothelial dysfunction and left ventricular (LV) dysfunction in patients with acute myocardial infarction (AMI).
METHODS: Plasma levels of PAI-1 activity and tissue-plasminogen activator (tPA) antigen were measured 2 weeks and 6 months after MI by ELISA in plasma obtained from the aortic root (AO) and anterior interventricular vein (AIV) in 28 patients with a first AMI due to occlusion of the left anterior descending coronary artery (LAD). Coronary blood flow responses in LAD to intracoronary infusion of acetylcholine (ACh) and left ventriculography were measured at the same time points: 2 weeks and 6 months after MI.
RESULTS: The trans-myocardial gradient of PAI-1 from AO to AIV, reflecting production/release of PAI-1 in the infarcted lesion, was inversely correlated with the coronary blood flow response to ACh 6 months after MI (r=-0.43, p=0.02) and with the percentage change in LV regional motion in the LAD territory from 2 weeks to 6 months after MI (r=-0.38, p=0.04). The trans-myocardial gradient of tPA level showed no significant correlations.
CONCLUSIONS: PAI-1 produced in the infarcted myocardium and released into the coronary circulation is associated with endothelial dysfunction in resistance vessels of the infarct-related coronary arteries and with progressive dysfunction of the infarcted region of the left ventricle in AMI survivors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26632165     DOI: 10.5551/jat.32300

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  5 in total

1.  MicroRNA-30b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor-1.

Authors:  Bin Li; Jie Hu; Xingpeng Chen
Journal:  Exp Ther Med       Date:  2018-04-10       Impact factor: 2.447

2.  Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression.

Authors:  Chiharu Takahashi; Makoto Kurano; Masako Nishikawa; Kuniyuki Kano; Tomotaka Dohi; Katsumi Miyauchi; Hiroyuki Daida; Tomo Shimizu; Junken Aoki; Yutaka Yatomi
Journal:  J Atheroscler Thromb       Date:  2017-03-17       Impact factor: 4.928

3.  Characterization of Cardiovascular Alterations Induced by Different Chronic Cisplatin Treatments.

Authors:  Esperanza Herradón; Cristina González; José A Uranga; Raquel Abalo; Ma I Martín; Visitacion López-Miranda
Journal:  Front Pharmacol       Date:  2017-05-08       Impact factor: 5.810

4.  Significant decrease of von Willebrand factor and plasminogen activator inhibitor-1 by providing supplementation with selenium and coenzyme Q10 to an elderly population with a low selenium status.

Authors:  Urban Alehagen; J Alexander; J Aaseth; A Larsson; T L Lindahl
Journal:  Eur J Nutr       Date:  2020-02-20       Impact factor: 5.614

Review 5.  C-Peptide as a Therapy for Type 1 Diabetes Mellitus.

Authors:  Rachel L Washburn; Karl Mueller; Gurvinder Kaur; Tanir Moreno; Naima Moustaid-Moussa; Latha Ramalingam; Jannette M Dufour
Journal:  Biomedicines       Date:  2021-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.